Skip to main content
Clinical Trials/NCT01004718
NCT01004718
Completed
Not Applicable

A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging

Abramson Cancer Center at Penn Medicine1 site in 1 country10 target enrollmentMay 2009
ConditionsLymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphoma
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
10
Locations
1
Primary Endpoint
Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Detailed Description

OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
November 5, 2014
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.

Exclusion Criteria

  • Pregnant or nursing,
  • Uncontrolled diabetes mellitus,
  • Active infection,
  • Inability to give informed consent or to comply with all study procedures,
  • Subjects may be excluded at the discretion of the principal investigator or study team members.

Outcomes

Primary Outcomes

Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration

Time Frame: 2 hours (between 60 minutes post-administration and 180 minutes post-administration)

Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).

Study Sites (1)

Loading locations...

Similar Trials